Fiche centre
Hospital Universitario y Politécnico La Fe
Valencia — Spain
Essais liés12clinical trials
VilleValencialocalisation
PaysSpainlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07037966
Essais cliniques associés
12| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| XEN1101 | Épilepsie | Phase 2 | NCT03796962 | X-TOLE — A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy | ACTIVE_NOT_RECRUITING |
| GNT0004 (1x10e13 vg/kg) | Myopathies | Phase 2/3 | NCT07856329 | A Clinical Study to Assess Safety, Efficacy and Pharmacodynamic Profile of GNT0004 in Duchenne Muscular Dystrophy | RECRUITING |
| MRI | SEP | Non applicable | NCT07037966 | Advancing Portable Brain Imaging: The NextMRI Project's Role in Revolutionizing Diagnostic MRI | COMPLETED |
| Zanidatamab | Cancer | Phase 3 | NCT06282575 | Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer | RECRUITING |
| VX-670 | Myopathies | Phase 1/2 | NCT06185764 | Galileo — A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | ACTIVE_NOT_RECRUITING |
| Givinostat | Myopathies | Phase 3 | NCT05933057 | ULYSSES — Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy | RECRUITING |
| SAT-3247 | Myopathies | Phase 2 | NCT07287189 | BASECAMP — Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients | ACTIVE_NOT_RECRUITING |
| Rimegepant 75mg daily dosing | Migraine | Phase 4 | NCT05217927 | Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens | COMPLETED |
| Rimegepant | Migraine | Phase 3 | NCT05156398 | Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects | RECRUITING |
| Botulinum toxin type A | Migraine | Phase 3 | NCT06047457 | E-BEOND — A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults | ACTIVE_NOT_RECRUITING |
| Botulinum toxin type A | Migraine | Phase 3 | NCT06047444 | C-BEOND — A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults | ACTIVE_NOT_RECRUITING |
| Quality of Life in Metastatic Breast Cancer (MBC) Patients in Second Line Monochemotherapy | Cancer | À vérifier | NCT02403869 | Quality of Life in Metastatic Breast Cancer (MBC) Patients in Second Line Monochemotherapy | COMPLETED |